Akums Reports Q2 FY26 Results; Strengthens International Presence

Akums Drugs & Pharmaceuticals Ltd., India’s Largest Contract Development and Manufacturing Organizations (CDMO), announced its financial results for the second quarter of FY26. The CDMO segment remained the key contributor with revenue of ¥804 crore, reflecting Akums’ position as preferred CMDO partner in India. The domestic Branded Formulations business recorded revenue of X122 crore, with EBITDA margins improving to 21.6%. The Branded Export segment maintained healthy EBITDA margin of 24.5%. The company reported consolidated revenue of ¥1,018 crore, EBITDA of ¥394 crore, and PAT of ¥43 crore for Q2 FY26. For the first half of FY26, revenue stood at ¥2,042 crore with an EBITDA of ¥3,223 crore and PAT of ¥107 crore. Akums recently made significant strides in expanding its global reach with the groundbreaking of a pharmaceutical plant in Zambia and the first commercial supply of formulations in Europe.